TABLE 2.
FC, CLA-CE, and CE content in activated P388D1 macrophages
| Treatments | FC (nmol/107 cells) | CLA-CE (nmol/107 cells) | CE (nmol/107 cells) | CLA/CE (%) | FC/CE |
| CTR | 187.92 ± 10.68 | 5.86 ± 0.56 | 78.60 ± 3.15 | 7.44 | 2.39 |
| CTR+LPS | 200.98 ± 0.67 | 5.48 ± 1.03 | 92.99 ± 8.08a | 5.86 | 2.17 |
| ACS | 203.56 ± 17.97 | 6.13 ± 1.60 | 50.72 ± 9.17c | 12.47 | 4.10c |
| ACS+LPS | 206.75 ± 5.81 | 6.19 ± 0.98 | 47.85 ± 0.76c | 12.96b | 4.32c |
| CRS | 222.66 ± 21.06c | 6.69 ± 1.05 | 43.82 ± 3.07c | 15.33b | 5.10c |
| CRS+LPS | 229.37 ± 2.41c | 6.76 ± 1.65 | 39.27 ± 3.54c | 17.06b | 5.87c |
FC, CLA-CE, total CE, and FC/CE were evaluated in P388D1 cells with/without LPS activation and in the absence (CTR) and presence of Sz-58035 (4 μM) for a period of 72 h (ACS) or 2 months (CRS).
a
P < 0.05 versus CTR without LPS.
b
P < 0.01 versus CTR and ACS without LPS.
c
P < 0.001 versus CTR ± LPS.